ANB032 did not meet the primary endpoint in moderate-to-severe atopic dermatitis

This study will evaluate the safety, tolerability, and efficacy of ANB032 in subjects with moderate to severe atopic dermatitis (AD).

This is a Phase 2, randomized, double blind, placebo controlled, parallel group, multicenter study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and immunogenicity of ANB032 in subjects with moderate to severe atopic dermatitis (AD).

Key Inclusion Criteria:

• Male or female aged 18 to 65 years and in good general health
• Moderate to severe AD for at least 6 months prior to Randomization
• History of inadequate response to treatment for AD with topical medications or for whom topical treatments are otherwise medically inadvisable
• EASI score ≥ 16 at Screening and at Randomization
• vIGA AD score ≥ 3 at Screening and at Randomization
• AD involved BSA ≥ 10% at Screening and at Randomization

Key Exclusion Criteria:

• Any factors that in the Investigator's opinion would predispose the subject to develop an infection
• Known or suspected congenital or acquired immunodeficiency state, or condition that would compromise the subject's immune status
• Not able to tolerate SC drug administration
• Tanning booth use or extended sun exposure that could affect disease severity or interfere with disease assessments within 4 weeks before Randomization